9209-030 
9209-031 
9209-032 
9209-033 
9212-034* 
9212-035* 
(M) Deisseroth. Albert EL University of Texas MD Anderson Cancer 
Center: Use of Retroviral Markers to Evaluate the Efficacy of Purg in g and 
to Discriminate Between Relapse which Arises from Systemic Disease 
Remaining after Preparative Therapy Versus Relapse due to Residual 
Neoplastic Cells in Autologous Marrow Following Purging in Patients with 
Chronic Lvmphocvtic Leukemia ( CLL ). 
Date of RAC Approval: 9-14-92 
(T) Roth. Jack A.. The University of Texas MD Anderson Cancer Center: 
Clinical Protocol for Modification of Oncogene and Tumor Suppressor 
Gene Expression in Non-Small Cell Lung Cancer, 
Date of RAC Approval: 9:1 5-92 
(M) Brenner, Malcolm K., St. Jude Children's Research Hospital; A Phase 
II Trial of the Baxter Neuroblastoma Bone Marrow Purging System Using 
Gene Marking to Assess Efficacy. 
Date of RAC Approval: 9-15-92 
Date of NIH Approval: 2-5-93 
(T) Lotze, Michael T. and Rubin, Joshua T., University of Pittsburgh; Gene 
Therapy of Cancer: A Pilot Study of IL-4 Gene Modified Antitumor 
Vaccines. 
Date of RAC Approval: 9-15-92 
Date of NIH Approval: 2-5-93 
(T) Crystal, Ronald G., National Heart, Lung, and Blood Institute; A Phase 
I Study, in Cystic Fibrosis Patients, of the Safety, Toxicity, and Biological 
Efficacy of a Single Administration of a Replication Deficient, 
Recombinant Adenovirus Carrying the cDNA of the Normal Human 
Cystic Fibrosis Transmembrane Conductance Regulator Gene in the 
Lung. 
Date of RAC Approval: 12-3-92 
Date of NIH Approval: 4-16-93 
Minor Modification: 5-17-93 
(T) Wilson, James M., University of Michigan; Gene Therapy of Cystic 
Fibrosis Lung Diseases Using El Deleted Adenoviruses: A Phase I Trial. 
Date of RAC Approval: 12-3-92 
Date of NIH Approval: 8-26-93 
Minor Modification: 8-17-93 
Recombinant DNA Research, Volume 18 
[233] 
